Advertisement

Endocrine

, Volume 63, Issue 3, pp 592–601 | Cite as

In vitro antitumor activity of progesterone in human adrenocortical carcinoma

  • Martina Fragni
  • Chiara Fiorentini
  • Elisa Rossini
  • Simona Fisogni
  • Sara Vezzoli
  • Sara A. Bonini
  • Cristina Dalmiglio
  • Salvatore Grisanti
  • Guido A. M. Tiberio
  • Melanie Claps
  • Deborah Cosentini
  • Valentina Salvi
  • Daniela Bosisio
  • Massimo Terzolo
  • Cristina Missale
  • Fabio Facchetti
  • Maurizio Memo
  • Alfredo BerrutiEmail author
  • Sandra Sigala
Original Article

Abstract

Purpose

The management of patients with adrenocortical carcinoma (ACC) is challenging. As mitotane and chemotherapy show limited efficacy, there is an urgent need to develop therapeutic approaches. The aim of this study was to investigate the antitumor activity of progesterone and explore the molecular mechanisms underlying its cytotoxic effects in the NCI-H295R cell line and primary cell cultures derived from ACC patients.

Methods

Cell viability, cell cycle, and apoptosis were analyzed in untreated and progesterone-treated ACC cells. The ability of progesterone to affect the Wnt/β-catenin pathway in NCI-H295R cells was investigated by immunofluorescence. Progesterone and mitotane combination experiments were also performed to evaluate their interaction on NCI-H295R cell viability.

Results

We demonstrated that progesterone exerted a concentration-dependent inhibition of ACC cell viability. Apoptosis was the main mechanism, as demonstrated by a significant increase of apoptosis and cleaved-Caspase-3 levels. Reduction of β-catenin nuclear translocation may contribute to the progesterone cytotoxic effect. The progesterone antineoplastic activity was synergically increased when mitotane was added to the cell culture medium.

Conclusions

Our results show that progesterone has antineoplastic activity in ACC cells. The synergistic cytotoxic activity of progesterone with mitotane provides the rationale for testing this combination in a clinical study.

Keywords

Adrenocortical carcinoma Progesterone Progesterone receptor Cell viability 

Abbreviations

ACC

adrenocortical carcinoma

PgR

progesterone receptor

IC

Interval of Confidence

MTT

3-(4,5-Dimethyl-2-thiazol)-2,5-diphenyl-2H-tetrazolium bromide

mPR

progesterone membrane receptor

PGRMC1

progesterone receptor membrane component 1

Notes

Funding

This work was supported by: AIRC project IG17678 (PI: M.T.); AIRC project IG14411 (PI: A.B.); Fondazione Camillo Golgi, Brescia; University of Brescia local grants; private donation of “gli Amici di Andrea” in memory of Andrea Gadeschi; private grant from the amateur dramatics group “Attori non per caso”, Parish church of Collio Valtrompia (Brescia). M.F. was supported by a grant from the Italian Society of Pharmacology.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

12020_2018_1795_MOESM1_ESM.docx (791 kb)
Supplementary data

References

  1. 1.
    C.L. Ronchi, M. Kroiss, S. Sbiera, T. Deutschbein, M. Fassnacht, EJE prize 2014: current and evolving treatment options in adrenocortical carcinoma: where do we stand and where do we want to go? Eur. J. Endocrinol. 171, R1–R11 (2014)CrossRefGoogle Scholar
  2. 2.
    M. Terzolo, F. Daffara, A. Ardito, B. Zaggia, V. Basile, L. Ferrari, A. Berruti, Management of adrenal cancer: a 2013 update. J. Endocrinol. Invest. 37, 207–217 (2014)CrossRefGoogle Scholar
  3. 3.
    A. Berruti, E. Baudin, H. Gelderblom, H.R. Haak, F. Porpiglia, M. Fassnacht, G. Pentheroudakis; ESMO Guidelines Working Group, Adrenal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23(Suppl 7), 131–138 (2012)CrossRefGoogle Scholar
  4. 4.
    M. Fassnacht, M. Terzolo, B. Allolio, E. Baudin, H. Haak, A. Berruti, S. Welin, C. Schade-Brittinger, A. Lacroix, B. Jarzab, H. Sorbye, D.J. Torpy, V. Stepan et al. Combination chemotherapy in advanced adrenocortical carcinoma. N. Engl. J. Med. 366, 2189–2197 (2012)CrossRefGoogle Scholar
  5. 5.
    A. Berruti, M. Terzolo, P. Sperone, A. Pia, S. Della Casa, D.J. Gross, C. Carnaghi, P. Casali, F. Porpiglia, F. Mantero, G. Reimondo, A. Angeli, L. Dogliotti, Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr. Relat. Cancer 12, 657–666 (2005)CrossRefGoogle Scholar
  6. 6.
    A. Berruti, M. Fassnacht, H. Haak, T. Else, E. Baudin, P. Sperone, M. Kroiss, T. Kerkhofs, A.R. Williams, A. Ardito, S. Leboulleux, M. Volante, T. Deutschbein, R. Feelders, C. Ronchi, S. Grisanti, H. Gelderblom, F. Porpiglia, M. Papotti, G.D. Hammer, B. Allolio, M. Terzolo, Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer. Eur. Urol. 65, 832–838 (2014)CrossRefGoogle Scholar
  7. 7.
    R. Libé, I. Borget, C.L. Ronchi, B. Zaggia, M. Kroiss, T. Kerkhofs, J. Bertherat, M. Volante, M. Quinkler, O. Chabre, M. Tabarin, F. Beuschlein et al.. Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Ann. Oncol. 26, 2119–2125 (2015)CrossRefGoogle Scholar
  8. 8.
    M. Volante, C. Buttigliero, E. Greco, A. Berruti, M. Papotti, Pathological and molecular features of adrenocortical carcinoma: an update. J. Clin. Pathol. 61, 787–793 (2008)CrossRefGoogle Scholar
  9. 9.
    S. Puglisi, P. Perotti, D. Cosentini, E. Roca, V. Basile, A. Berruti, M. Terzolo, Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options. Expert. Rev. AntiCancer Ther. 8(11), 1–9 (2018)Google Scholar
  10. 10.
    C. Fiorentini, M. Fragni, P. Perego, S. Vezzoli, S.A. Bonini, M. Tortoreto, D. Galli, M. Claps, G.A. Tiberio, M. Terzolo, C. Missale, M. Memo, G. Procopio, N. Zaffaroni, A. Berruti, S. Sigala, Antisecretive and antitumor activity of abiraterone acetate in human adrenocortical cancer: a preclinical study. J. Clin. Endocrinol. Metab. 101, 4594–4602 (2016)CrossRefGoogle Scholar
  11. 11.
    G. Attard, A.H. Reid, R.J. Auchus, B.A. Hughes, A.M. Cassidy, E. Thompson, N.B. Oommen, E. Folkerd, M. Dowsett, W. Arlt, J.S. de Bono, Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J. Clin. Endocrinol. Metab. 97, 507–516 (2012)CrossRefGoogle Scholar
  12. 12.
    A. Pia, F. Vignani, G. Attard, M. Tucci, P. Bironzo, G. Scagliotti, W. Arlt, M. Terzolo, A. Berruti, Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone. Cancer Treat. Rev. 39, 966–973 (2013)CrossRefGoogle Scholar
  13. 13.
    M. Claps, B. Lazzari, S. Grisanti, V. Ferrari, M. Terzolo, S. Sigala, S. Vezzoli, M. Memo, M. Castellano, A. Berruti, Management of severe Cushing’s syndrome induced by adrenocortical carcinoma with abiraterone acetate: a case report. AACE Clin. Rep. 2, 337–341 (2016)CrossRefGoogle Scholar
  14. 14.
    A. Salomon, M. Keramidas, C. Maisin, M. Thomas, Loss of β-catenin in adrenocortical cancer cells causes growth inhibition and reversal of epithelial-to-mesenchymal transition. Oncotarget 6, 11421–11433 (2015)CrossRefGoogle Scholar
  15. 15.
    D. Garg, S.S.M. Ng, K.M. Baig, P. Driggers, J. Segars, Progesterone-mediated non-classical signaling. Trends Endocrinol. Metab. 28, 656–668 (2017)CrossRefGoogle Scholar
  16. 16.
    R.L. Ashley, C.M. Clay, T.A. Farmerie, G.D. Niswender, T.M. Nett, Cloning and characterization of an ovine intracellular seven transmembrane receptor for progesterone that mediates calcium mobilization. Endocrinology 147, 4151–4159 (2006)CrossRefGoogle Scholar
  17. 17.
    V. Boonyaratanakornkit, N. Hamilton, D.C. Márquez-Garbán, P. Pateetin, E.M. McGowan, R.J. Pietras, Extranuclear signaling by sex steroid receptors and clinical implications in breast cancer. Mol. Cell. Endocrinol. 466, 51–72 (2018)CrossRefGoogle Scholar
  18. 18.
    W.E. Rainey, K. Saner, B.P. Schimmer, Adrenocortical cell lines. Mol. Cell. Endocrinol. 228, 23–38 (2004)CrossRefGoogle Scholar
  19. 19.
    E.N. Kornaga, A.C. Klimowicz, N. Guggisberg, T. Ogilvie, D.G. Morris, M. Webster, A.M. Magliocco, A systematic comparison of three commercial estrogen receptor assays in a single clinical outcome breast cancer cohort. Mod. Pathol. 29, 799–809 (2016)CrossRefGoogle Scholar
  20. 20.
    T.C. Chou, P. Talalay, Quantitative analysis of dose−effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzym. Regul. 22, 27–55 (1984)CrossRefGoogle Scholar
  21. 21.
    T.C. Chou, Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621–681 (2006)CrossRefGoogle Scholar
  22. 22.
    J. Hofman, D. Ahmadimoghaddam, L. Hahnova, P. Pavek, M. Ceckova, F. Staud, Olomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone. Pharmacol. Res. 65, 312–319 (2012)CrossRefGoogle Scholar
  23. 23.
    S. Sigala, S. Bodei, C. Missale, D. Zani, C. Simeone, S.C. Cunico, P.F. Spano, Gene expression profile of prostate cancer cell lines: effect of nerve growth factor treatment. Mol. Cell. Endocrinol. 284, 11–20 (2008)CrossRefGoogle Scholar
  24. 24.
    C. Fiorentini, S. Bodei, F. Bedussi, M. Fragni, S.A. Bonini, C. Simeone, D. Zani, A. Berruti, C. Missale, M. Memo, P.F. Spano, S. Sigala, GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity. Exp. Cell Res. 323, 100–111 (2014)CrossRefGoogle Scholar
  25. 25.
    V. Porrini, I. Sarnico, M. Benarese, C. Branca, M. Mota, A. Lanzillotta, A. Bellucci, E. Parrella, L. Faggi, P.F. Spano, B.P. Imbimbo, M. Pizzi, Neuroprotective and anti-apoptotic efects of CSP-1103 in primary cortical neurons exposed to oxygen and glucose deprivation. Int. J. Mol. Sci. 18, E184 (2017)CrossRefGoogle Scholar
  26. 26.
    M. Babagana, S. Johnson, H. Slabodkin, W. Bshara, C. Morrison, E.S. Kandel, P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells. Mol. Carcinog. 56, 1515–1525 (2017)CrossRefGoogle Scholar
  27. 27.
    N.M. Bashour, S. Wray, Progesterone directly and rapidly inhibits GnRH neuronal activity via progesterone receptor membrane component 1 endocrinology. Endocrinology 153, 4457–4469 (2012)CrossRefGoogle Scholar
  28. 28.
    V. Lodde, J.J. Peluso, A novel role for progesterone and progesterone receptor membrane component 1 in regulating spindle microtubule stability during rat and human ovarian cell mitosis. Biol. Reprod. 84, 715–722 (2011)CrossRefGoogle Scholar
  29. 29.
    A. Chimento, R. Sirianni, I. Casaburi, F. Zolea, P. Rizza, P. Avena, R. Malivindi, A. De Luca, C. Campana, E. Martire, F. Domanico, F. Fallo, G. Carpinelli, L. Cerquetti, D. Amendola, A. Stigliano, V. Pezzi, GPER agonist G-1 decreases adrenocortical carcinoma (ACC) cell growth in vitro and in vivo. Oncotarget 6, 19190–19203 (2015)CrossRefGoogle Scholar
  30. 30.
    R.S.Y. Wong, Apoptosis in cancer: from pathogenesis to treatment. J. Exp. Clin. Cancer Res. 30, 87 (2011)Google Scholar
  31. 31.
    A.O. Mueck, X. Ruan, H. Seeger, T. Fehm, H. Neubauer, Genomic and non-genomic actions of progestogens in the breast. J. Steroid Biochem. Mol. Biol. 142, 62–67 (2014)CrossRefGoogle Scholar
  32. 32.
    T. Wang, W.E. Rainey, Human adrenocortical carcinoma cell lines. Mol. Cell. Endocrinol. 351, 58–65 (2012)CrossRefGoogle Scholar
  33. 33.
    K.M. Scarpin, J.D. Graham, P.A. Mote, C.L. Clarke, Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression. Nucl. Recept. Signal. 7, e009 (2009)CrossRefGoogle Scholar
  34. 34.
    J.H. Check, The role of progesterone and the progesterone receptor in cancer. Expert Rev. Endocrinol. Metab. 12, 187–197 (2017)CrossRefGoogle Scholar
  35. 35.
    A. Leibovitz, W.M. McCombs 3rd, D. Johnston, C.E. McCoy, J.C. Stinson, New human cancer cell culture lines. I. SW-13, small-cell carcinoma of the adrenal cortex. J. Natl. Cancer Inst. 51, 691–697 (1973)Google Scholar
  36. 36.
    V. Boonyaratanakornkit, E. McGowan, L. Sherman, M.A. Mancini, B.J. Cheskis, D.P. Edwards, The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. Mol. Endocrinol. 21, 359–375 (2007)CrossRefGoogle Scholar
  37. 37.
    S.Z. Bu, D.L. Yin, X.H. Ren, L.Z. Jiang, Z.J. Wu, Q.R. Gao, G. Pei, Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines. Cancer 79, 1944–1950 (1997)CrossRefGoogle Scholar
  38. 38.
    V. Syed, S.M. Ho, Progesterone-induced apoptosis in immortalized normal and malignant human ovarian surface epithelial cells involves enhanced expression of FasL. Oncogene 22, 6883–6890 (2003)CrossRefGoogle Scholar
  39. 39.
    B. Formby, T.S. Wiley, Bcl-2, survivin and variant CD44 v7-v10 are downregulated and p53 is upregulated in breast cancer cells by progesterone: inhibition of cell growth and induction of apoptosis. Mol. Cell. Biochem. 202, 53–61 (1999)CrossRefGoogle Scholar
  40. 40.
    K. Horita, N. Inase, S. Miyake, B. Formby, H. Toyoda, Y. Yoshizawa, Progesterone induces apoptosis in malignant mesothelioma cells. Anticancer Res. 21, 3871–3874 (2001)Google Scholar
  41. 41.
    F. Atif, S. Yousuf, D.G. Stein, Anti-tumor effects of progesterone in human glioblastoma multiforme: role of PI3K/Akt/mTOR signaling. J. Steroid Biochem. Mol. Biol. 146, 62–73 (2015)CrossRefGoogle Scholar
  42. 42.
    Y. Wang, P. Hanifi-Moghaddam, E.E. Hanekamp, H.J. Kloosterboer, P. Franken, J. Veldscholte, H.C. van Doorn, P.C. Ewing, J.J. Kim, J.A. Grootegoed, C.W. Burger, R. Fodde, L.J. Blok, Progesterone inhibition of Wnt/beta-catenin signaling in normal endometrium and endometrial cancer. Clin. Cancer Res. 15, 5784–5793 (2009)CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Martina Fragni
    • 1
  • Chiara Fiorentini
    • 1
  • Elisa Rossini
    • 1
  • Simona Fisogni
    • 2
  • Sara Vezzoli
    • 1
  • Sara A. Bonini
    • 1
  • Cristina Dalmiglio
    • 3
  • Salvatore Grisanti
    • 3
  • Guido A. M. Tiberio
    • 4
  • Melanie Claps
    • 3
  • Deborah Cosentini
    • 3
  • Valentina Salvi
    • 5
  • Daniela Bosisio
    • 5
  • Massimo Terzolo
    • 6
  • Cristina Missale
    • 1
  • Fabio Facchetti
    • 2
  • Maurizio Memo
    • 1
  • Alfredo Berruti
    • 3
    Email author
  • Sandra Sigala
    • 1
  1. 1.Section of Pharmacology, Department of Molecular and Translational MedicineUniversity of BresciaBresciaItaly
  2. 2.Pathology Unit, Department of Molecular and Translational MedicineUniversity of Brescia and ASST Spedali Civili di BresciaBresciaItaly
  3. 3.Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public HealthUniversity of Brescia and ASST Spedali Civili di BresciaBresciaItaly
  4. 4.Surgical Clinic, Department of Clinical and Experimental SciencesUniversity of Brescia and ASST Spedali Civili di BresciaBresciaItaly
  5. 5.Section of Oncology and Experimental Immunology, Department of Molecular and Translational MedicineUniversity of BresciaBresciaItaly
  6. 6.Department of Clinical and Biological Sciences University of Turin, Internal Medicine 1San Luigi Gonzaga HospitalOrbassanoItaly

Personalised recommendations